The present invention provides for compositions of anti-M-CSF antibodies comprising a chelating agent and/or histidine. Also provided are methods of treating M-CSF-mediated disorders with pharmaceutical formulations of anti-M-CSF antibodies, including inflammatory diseases and neoplasia disorders.